Eur J Cancer Care:荟萃分析表明miR-146a rs2910164是胃癌发生的危险因素

2017-10-24 MedSci MedSci原创

既往研究探究了miR-146a rs2910164与胃癌(GC)发生风险之间的相关性,但结果尚未确定。 为了更准确的评估二者之间的关联,本研究进行了荟萃分析。研究人员检索了2014年7月之前PubMed和中国知网在线发布的相关文章。使用stat 11.0对进行荟萃分析。结果共选择了7个病例对照研究,包括3283例病例和4535例对照者。所有遗传模型(CC VS. GG,OR = 0.76,95%C

既往研究探究了miR-146a rs2910164与胃癌(GC)发生风险之间的相关性,但结果尚未确定。 为了更准确的评估二者之间的关联,本研究进行了荟萃分析。

研究人员检索了2014年7月之前PubMed和中国知网在线发布的相关文章。使用stat 11.0对进行荟萃分析。结果共选择了7个病例对照研究,包括3283例病例和4535例对照者。所有遗传模型(CC VS. GG,OR = 0.76,95%CI = 0.66-0.87;CC VS. GC + GG,OR = 0.84,95%CI = 0.71-0.99)中均发现rs2910164和GC风险之间存在明显的相关关系;CC + GC VS. GG,OR = 0.82,95%CI = 0.73-0.91)。种族亚组分析发现,亚洲人群中此种关联存在明显的统计差异。

总之,该荟萃分析表明miR-146a rs2910164是GC发生的危险因素。

原始出处:


Sun Y, Li M. Genetic polymorphism of miR-146a is associated with gastric cancer risk: a meta-analysis. Eur J Cancer Care (Engl). 2017 Mar;26(2). doi: 10.1111/ecc.12355. Epub 2015 Jul 23.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1930526, encodeId=53c51930526a8, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Feb 27 09:51:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681355, encodeId=409a1681355d6, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 08 10:51:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836923, encodeId=cc5d183692374, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Oct 25 15:51:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036283, encodeId=bbb420362832a, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Mon Aug 06 23:51:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255635, encodeId=1b79255635a8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/b78b270b134d3c9c0bfe231781ec5336.jpg, createdBy=afb62179712, createdName=1206d468m59(暂无昵称), createdTime=Tue Oct 24 15:10:41 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255632, encodeId=81d025563279, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Oct 24 15:03:09 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
    2018-02-27 smallant2002
  2. [GetPortalCommentsPageByObjectIdResponse(id=1930526, encodeId=53c51930526a8, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Feb 27 09:51:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681355, encodeId=409a1681355d6, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 08 10:51:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836923, encodeId=cc5d183692374, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Oct 25 15:51:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036283, encodeId=bbb420362832a, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Mon Aug 06 23:51:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255635, encodeId=1b79255635a8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/b78b270b134d3c9c0bfe231781ec5336.jpg, createdBy=afb62179712, createdName=1206d468m59(暂无昵称), createdTime=Tue Oct 24 15:10:41 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255632, encodeId=81d025563279, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Oct 24 15:03:09 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
    2018-09-08 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1930526, encodeId=53c51930526a8, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Feb 27 09:51:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681355, encodeId=409a1681355d6, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 08 10:51:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836923, encodeId=cc5d183692374, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Oct 25 15:51:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036283, encodeId=bbb420362832a, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Mon Aug 06 23:51:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255635, encodeId=1b79255635a8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/b78b270b134d3c9c0bfe231781ec5336.jpg, createdBy=afb62179712, createdName=1206d468m59(暂无昵称), createdTime=Tue Oct 24 15:10:41 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255632, encodeId=81d025563279, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Oct 24 15:03:09 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1930526, encodeId=53c51930526a8, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Feb 27 09:51:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681355, encodeId=409a1681355d6, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 08 10:51:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836923, encodeId=cc5d183692374, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Oct 25 15:51:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036283, encodeId=bbb420362832a, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Mon Aug 06 23:51:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255635, encodeId=1b79255635a8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/b78b270b134d3c9c0bfe231781ec5336.jpg, createdBy=afb62179712, createdName=1206d468m59(暂无昵称), createdTime=Tue Oct 24 15:10:41 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255632, encodeId=81d025563279, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Oct 24 15:03:09 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
    2018-08-06 feifers
  5. [GetPortalCommentsPageByObjectIdResponse(id=1930526, encodeId=53c51930526a8, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Feb 27 09:51:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681355, encodeId=409a1681355d6, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 08 10:51:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836923, encodeId=cc5d183692374, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Oct 25 15:51:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036283, encodeId=bbb420362832a, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Mon Aug 06 23:51:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255635, encodeId=1b79255635a8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/b78b270b134d3c9c0bfe231781ec5336.jpg, createdBy=afb62179712, createdName=1206d468m59(暂无昵称), createdTime=Tue Oct 24 15:10:41 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255632, encodeId=81d025563279, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Oct 24 15:03:09 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
    2017-10-24 1206d468m59(暂无昵称)

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1930526, encodeId=53c51930526a8, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Feb 27 09:51:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681355, encodeId=409a1681355d6, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 08 10:51:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836923, encodeId=cc5d183692374, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Oct 25 15:51:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036283, encodeId=bbb420362832a, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Mon Aug 06 23:51:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255635, encodeId=1b79255635a8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/b78b270b134d3c9c0bfe231781ec5336.jpg, createdBy=afb62179712, createdName=1206d468m59(暂无昵称), createdTime=Tue Oct 24 15:10:41 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255632, encodeId=81d025563279, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Oct 24 15:03:09 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
    2017-10-24 清风拂面

    谢谢分享.学习了

    0

相关资讯

错把胃癌当胃炎治,医院赔偿3.1万,应该吗?

医学的事谁能说得清呢?真到了那时候,赔再多钱,能换回命么?

Cancer Sci:肿瘤和血清中的LRG1或可用于胃癌患者的预后分析

胃癌是最常见的恶性肿瘤之一。尽管化疗有所改善,但晚期胃癌的临床预后依然很差。因此,预测预后越来越重要,并且确定患者是否应该接受新辅助化疗或辅助化疗。富含亮氨酸的α2-糖蛋白-1(LRG 1)在炎症过程中过表达,与各种恶性肿瘤有关。在本研究中,我们评估癌症标本和癌症患者血清中的LRG 1表达,以阐明LRG 1作为胃癌生物标志物的有效性。本研究纳入239例(免疫组织化学染色; IHC)和184例(EL

徐瑞华:免疫靶向在胃癌治疗中的价值和探索

胃癌恶性程度高、预后差。早期胃癌通过D2切除术可取得治愈机会,其中Ⅱ、Ⅲ期胃癌通过辅助化疗,5年内复发风险仍达约1/3。晚期胃癌以姑息治疗为目的,治疗方案有限,目前中位总生存仅约1年左右。化疗药物的探索达到平台期,传统分子靶向药物研发也未有较大进展。而随着免疫靶向治疗在多个癌种中取得巨大成功,已有数种抗PD-1/PD-L1治疗药物在多种恶性肿瘤的治疗中取得了一定的适应症。近三年,免疫靶向治疗在胃癌

Lancet:Nivolumab为晚期胃癌或胃-食管结合部肿瘤患者带来生存获益

接受过两种或以上化疗方案治疗的晚期胃癌或胃-食管结合部肿瘤患者通常预后欠佳,并且对于这一部分患者,目前指南并没有特殊推荐某一种治疗方式。Nivolumab是PD-1的单克隆抗体抑制剂,本项研究旨在评价nivolumab对之前接受过两种或以上化疗方案治疗的晚期胃癌或胃-食管结合部肿瘤的有效性和安全性,相关研究成果发表在Lancet。

Onco Targets Ther:circ-104916或是胃癌的新的潜在肿瘤抑制因子和生物标志物

循环RNA是一大类非编码RNA,作为基因调节剂显示出了巨大的功能。最近的证据表明循环RNA与许多疾病特别是癌症有关。然而,很少有研究探究胃癌(GC)中循环RNA的表达和功能。在本研究中,研究人员发现GC组织和细胞系中,circ-104916的表达下调。circ-104916表达较低与较深的侵袭深度、更高的肿瘤分期和更频繁的淋巴转移相关。circ-104916过表达有效抑制了GC细胞在体外的增殖、迁

Aging:研究发现参与调节胃癌细胞增殖的新机制

虽然研究已经发现CircRNA_100269是可用于预测癌症复发的生物标志物,但其在胃癌(GC)中的表达和功能目前尚未可知。在本研究中,研究人员研究了circRNA_100269的表达及其潜在的下游miRNA靶标。此外,研究还阐明了在GC细胞系中circRNA_100269的分子功能和调控机制。研究人员在GC组织中发现circRNA_100269及其线性异构体LPHN2 mRNA的表达水平下调(p